Max Reinhardt
Insider
First SEC filing: June 12, 2024 · Latest: June 12, 2024
Insider at
Insider transactions
0 buys (P)
2 sells (S)
Net: $-27,169
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| March 5, 2026 | OFIX | S | 1,053 | $12.55 | $13,215 | 25,348 Direct | -3.99% | Disposed | -25.0% (price as of 2026-10-06) |
| March 4, 2026 | OFIX | S | 1,080 | $12.92 | $13,954 | 26,401 Direct | -3.93% | Disposed | -27.2% (price as of 2026-10-06) |
| June 11, 2025 | OFIX | S | 1,643 | $11.64 | $19,125 | 27,481 Direct | -5.64% | Disposed | -19.2% (price as of 2026-10-06) |
| March 3, 2025 | OFIX | A | 34,924 | · | · | 34,924 Direct | · | Acquired | (price as of 2026-10-06) |
| March 3, 2025 | OFIX | A | 14,723 | · | · | 29,124 Direct | +102.24% | Acquired | (price as of 2026-10-06) |
| June 10, 2024 | OFIX | A | 190,731 | · | · | 190,731 Direct | · | Acquired | (price as of 2026-10-06) |
| June 10, 2024 | OFIX | A | 14,401 | $13.02 | $187,501 | 14,401 Direct | · | Acquired | -27.7% (price as of 2026-10-06) |
| June 7, 2023 | PCRX | S | 1,099 | $37.86 | $41,608 | 29,225 Direct | -3.62% | Disposed | -34.6% (price as of 2026-10-06) |
| June 6, 2023 | PCRX | S | 1,054 | $38.99 | $41,095 | 30,324 Direct | -3.36% | Disposed | -36.5% (price as of 2026-10-06) |
| Oct. 7, 2022 | PCRX | S 10b5-1 | 1,380 | $58.00 | $80,040 | 31,378 Direct | -4.21% | Disposed | -57.3% (price as of 2026-10-06) |
| June 8, 2022 | PCRX | A | 19,900 | · | · | 19,900 Direct | · | Acquired | (price as of 2026-10-06) |
| June 8, 2022 | PCRX | A | 7,950 | · | · | 32,250 Direct | +32.72% | Acquired | (price as of 2026-10-06) |
| June 7, 2022 | PCRX | S 10b5-1 | 2,433 | $62.00 | $150,846 | 24,400 Direct | -9.07% | Disposed | -60.1% (price as of 2026-10-06) |
| June 6, 2022 | PCRX | S 10b5-1 | 2,817 | $61.37 | $172,879 | 26,833 Direct | -9.50% | Disposed | -59.7% (price as of 2026-10-06) |
| April 21, 2022 | PCRX | M | 12,500 | · | · | 100,000 Direct | -11.11% | Disposed | (price as of 2026-10-06) |
| April 21, 2022 | PCRX | S 10b5-1 | 9,824 | $73.25 | $719,608 | 29,650 Direct | -24.89% | Disposed | -66.2% (price as of 2026-10-06) |
| April 21, 2022 | PCRX | M 10b5-1 | 12,500 | $42.54 | $531,750 | 39,474 Direct | +46.34% | Acquired | -41.8% (price as of 2026-10-06) |
| April 20, 2022 | PCRX | M | 12,500 | · | · | 112,500 Direct | -10.00% | Disposed | (price as of 2026-10-06) |
| April 20, 2022 | PCRX | S 10b5-1 | 9,764 | $73.99 | $722,438 | 26,974 Direct | -26.58% | Disposed | -66.5% (price as of 2026-10-06) |
| April 20, 2022 | PCRX | M 10b5-1 | 12,500 | $42.54 | $531,750 | 36,738 Direct | +51.57% | Acquired | -41.8% (price as of 2026-10-06) |
| April 19, 2022 | PCRX | M | 12,500 | · | · | 125,000 Direct | -9.09% | Disposed | (price as of 2026-10-06) |
| April 19, 2022 | PCRX | S 10b5-1 | 9,321 | $72.25 | $673,442 | 24,238 Direct | -27.77% | Disposed | -65.7% (price as of 2026-10-06) |
| April 19, 2022 | PCRX | M 10b5-1 | 12,500 | $42.54 | $531,750 | 33,559 Direct | +59.36% | Acquired | -41.8% (price as of 2026-10-06) |
| April 18, 2022 | PCRX | M | 12,500 | · | · | 137,500 Direct | -8.33% | Disposed | (price as of 2026-10-06) |
| April 18, 2022 | PCRX | S 10b5-1 | 8,941 | $73.55 | $657,611 | 21,059 Direct | -29.80% | Disposed | -66.3% (price as of 2026-10-06) |
| April 18, 2022 | PCRX | M 10b5-1 | 12,500 | $42.54 | $531,750 | 30,000 Direct | +71.43% | Acquired | -41.8% (price as of 2026-10-06) |
| July 2, 2021 | PCRX | S 10b5-1 | 421 | $59.76 | $25,159 | 17,500 Direct | -2.35% | Disposed | -58.6% (price as of 2026-10-06) |
| June 9, 2021 | PCRX | A | 7,000 | · | · | 17,500 Direct | +66.67% | Acquired | (price as of 2026-10-06) |
| June 9, 2021 | PCRX | A | 17,500 | · | · | 17,500 Direct | · | Acquired | (price as of 2026-10-06) |
| June 7, 2021 | PCRX | S 10b5-1 | 2,278 | $60.50 | $137,819 | 10,500 Direct | -17.83% | Disposed | -59.1% (price as of 2026-10-06) |
| June 4, 2021 | PCRX | S 10b5-1 | 1,222 | $61.04 | $74,591 | 12,778 Direct | -8.73% | Disposed | -59.4% (price as of 2026-10-06) |
| Jan. 6, 2021 | PCRX | S 10b5-1 | 110 | $60.81 | $6,689 | 14,000 Direct | -0.78% | Disposed | -59.3% (price as of 2026-10-06) |
| Nov. 13, 2020 | PCRX | M | 25,000 | · | · | 150,000 Direct | -14.29% | Disposed | (price as of 2026-10-06) |
| Nov. 13, 2020 | PCRX | S 10b5-1 | 21,000 | $63.51 | $1,333,710 | 14,000 Direct | -60.00% | Disposed | -61.0% (price as of 2026-10-06) |
| Nov. 13, 2020 | PCRX | S 10b5-1 | 4,000 | $62.67 | $250,680 | 35,000 Direct | -10.26% | Disposed | -60.5% (price as of 2026-10-06) |
| Nov. 13, 2020 | PCRX | M 10b5-1 | 25,000 | $42.54 | $1,063,500 | 39,000 Direct | +178.57% | Acquired | -41.8% (price as of 2026-10-06) |
| Sept. 17, 2020 | PCRX | M | 25,000 | · | · | 175,000 Direct | -12.50% | Disposed | (price as of 2026-10-06) |
| Sept. 17, 2020 | PCRX | S 10b5-1 | 2,888 | $60.26 | $174,031 | 14,000 Direct | -17.10% | Disposed | -58.9% (price as of 2026-10-06) |
| Sept. 17, 2020 | PCRX | S 10b5-1 | 22,532 | $59.75 | $1,346,287 | 16,888 Direct | -57.16% | Disposed | -58.6% (price as of 2026-10-06) |
| Sept. 17, 2020 | PCRX | M 10b5-1 | 25,000 | $42.54 | $1,063,500 | 39,000 Direct | +178.57% | Acquired | -41.8% (price as of 2026-10-06) |
| June 9, 2020 | PCRX | A | 35,000 | · | · | 35,000 Direct | · | Acquired | (price as of 2026-10-06) |
| June 9, 2020 | PCRX | A | 14,000 | · | · | 14,000 Direct | · | Acquired | (price as of 2026-10-06) |
| July 2, 2019 | PCRX | A | 200,000 | · | · | 200,000 Direct | · | Acquired | (price as of 2026-10-06) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 3, 2025 | OFIX | Employee Stock Option (Right to Buy) | Common Stock | $16.98 | March 3, 2032 | 34,924 | Acquired |
| June 10, 2024 | OFIX | Employee Stock Option (Right to Buy) | Common Stock | $13.02 | June 10, 2031 | 190,731 | Acquired |
| June 8, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock | $59.39 | June 8, 2032 | 19,900 | Acquired |
| April 21, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock | $42.54 | July 2, 2029 | 12,500 | Disposed |
| April 20, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock | $42.54 | July 2, 2029 | 12,500 | Disposed |
| April 19, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock | $42.54 | July 2, 2029 | 12,500 | Disposed |
| April 18, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock | $42.54 | July 2, 2029 | 12,500 | Disposed |
| June 9, 2021 | PCRX | Stock Option (Right to Buy) | Common Stock | $60.96 | June 9, 2031 | 17,500 | Acquired |
| Nov. 13, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock | $42.54 | July 2, 2029 | 25,000 | Disposed |
| Sept. 17, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock | $42.54 | July 2, 2029 | 25,000 | Disposed |
| June 9, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock | $47.65 | June 9, 2030 | 35,000 | Acquired |
| July 2, 2019 | PCRX | Stock Option (Right to Buy) | Common Stock | $42.54 | July 2, 2029 | 200,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $258,462 | · | · | · | $301,392 | · | $429,146 | $2,783,328 |
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2019 | $266,000 | $140,000 | · | $4,145,775 | · | · | $23,263 | $4,575,038 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.